



www.stada.com

Pharmaceuticals

Acquired
August 2017

HQ
Germany
(global operations)

How we create value

The acquisition of STADA was originated by Cinven's Healthcare team, who, together with Cinven's German team, identified STADA as a well-positioned European pharmaceuticals manufacturer of prescription generics and over-the-counter products, with significant untapped potential for future growth.

Cinven is working with the STADA management team and its cosponsor to drive and optimise growth and to build a world-class organisation. The investment strategy focuses on new product development; international expansion; a targeted buy and build strategy; and implementing best practices in operations, cost management and governance.

Developments in 2017

In August 2017, Cinven's and its cosponsor's voluntary public offer for STADA was accepted. While the business remained publicly listed, at year end in February 2018, conclusion of the Domination and Profit and Loss Transfer Agreement (DPLTA) was approved by a voting majority of more than 99%. This marked a significant milestone in the investment. Following implementation of DPLTA, Cinven and its fellow shareholders' Value Creation Plan formally commenced.

STADA's management team was strengthened during 2017. Claudio Albrecht was appointed interim CEO, and Mark Keatley was appointed CFO, roles they previously held at Actavis Group. Post year end, in February 2018, Peter Goldschmidt (formerly President and Head of North America of Sandoz USA) was announced as STADA's new CEO. Peter will join STADA on 1 September 2018.

Employees
10,000
(approximate)